MBIO - Mustang Bio Publishes Phase 1 Trial Evaluating MB-101 in Nature Medicine

2024-03-07 08:57:32 ET

DENVER, Colo., Mar 07, 2024 ( 247marketnews.com )- Mustang Bio, Inc. (NASDAQ: MBIO ) reported, this morning, that it published Phase 1 clinical data in Nature Medicine that demonstrated Mustang’s MB-101 (IL13Ra2-targeted CAR T-cells) promising safety and clinical activity for the treatment of patients with recurrent and refractory malignant glioma, including glioblastoma.

Mustang Bio is trading at $1.41, up $0.09 (+6.82%), on 2.7M shares.

Mustang has the exclusive license to Mustang MB-101, which was developed by City of Hope, one of the largest cancer research and treatment organizations in the United States, and this is the largest reported trial to date of CAR-T therapy for solid tumors

Dr. Christine Brown, Heritage Provider Network Professor in Immunotherapy, deputy director of the T-Cell Therapeutics Research Laboratories at City of Hope, and lead author on the publication, said, “These Phase 1 clinical trial results represent a significant step forward in our understanding of the potential of MB-101 CAR T-cell therapy to treat recurrent GBM, an extremely aggressive tumor with very limited treatment options. One of the main challenges for treating brain cancer is that medications have difficulty crossing the blood-brain barrier. To overcome that barrier, the trial delivered CAR T-cells directly into the brain tumor and the cerebrospinal fluid, the fluid that protects and surrounds the brain and spinal cord. Repetitive locoregional administration of IL13R?2-CAR T-cells was feasible and well-tolerated with no dose limiting toxicities, even at the highest dose level of 200 x 10 ⁶ CAR T-cells per infusion. The safety and promising therapy-related bioactivity data pave the way for future studies of MB-101 and offer hope for a transformative treatment approach. We look forward to continuing our work with Mustang on this promising therapy.”

Manuel Litchman, M.D., President and Chief Executive Officer of Mustang, said, “MB-101 has demonstrated compelling therapeutic potential, including delivering unprecedented complete responses in two high-grade glioma patients; the first patient who achieved a complete response was published in The New England Journal of Medicine . These two patients treated solely with MB-101 both had high levels of intratumoral CD3+ T-cells pre-therapy (i.e., “hot” tumors) and achieved complete responses lasting 7.5 and 66+ months, respectively. This trial has led to several other studies using MB-101, including supporting our upcoming novel combination clinical trial of MB-109 [MB-101 (IL-13R?2 targeted CAR T-cell therapy) + MB-108 (HSV-1 oncolytic virus)] to improve treatment of recurrent GBM and high-grade astrocytoma. The combination leverages initial treatment with MB-108 to reshape the tumor microenvironment and make immunologically “cold” tumors “hot,” thereby potentially enabling the MB-101 CAR T-cell therapy to achieve efficacy equivalent to that seen in intrinsically “hot” tumors in this City of Hope Phase 1 trial.”

The post Mustang Bio Publishes Phase 1 Trial Evaluating MB-101 in Nature Medicine appeared first on 24/7 MarketNews .

For further details see: